Remove 2018 Remove Engineering Remove Licensing
article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

These include engineering the cells to express cytokines that promote their maturation and/or differentiation, and engineering drug-resistant γδ T cells that can be combined with chemotherapies, which stress cancer cells but would otherwise also deplete the T-cell population. Trends Immunol 39(6):446-459 (2018).

Therapies 105
article thumbnail

Crescendo Biologics Expands its Ongoing Collaboration with Takeda

The Pharma Data

Under its ongoing collaboration and license agreement, Crescendo’s proprietary transgenic platform and engineering expertise is being used to build Humabody ® -based therapeutics against certain targets selected by Takeda. This is the sixth technical milestone achieved by Crescendo in its collaboration with Takeda.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Innate Pharma 2021 Financial Calendar

The Pharma Data

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. About Innate Pharma: Innate Pharma S.A. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia.

article thumbnail

ARVINAS AND PFIZER ANNOUNCE GLOBAL COLLABORATION TO DEVELOP AND COMMERCIALIZE PROTAC® PROTEIN DEGRADER ARV-471

The Pharma Data

The two companies had previously announced in 2018 a separate research collaboration and license agreement for the discovery and development of drug candidates using Arvinas’ PROTAC technology. Terms of the Collaboration. The agreement is a worldwide co-development and co-commercialization collaboration.

article thumbnail

First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca

The Pharma Data

Monalizumab may re-establish a broad anti-tumor response mediated by NK and T cells, and may enhance the cytotoxic potential of other therapeutic antibodies (André et al, Cell 2018). AstraZeneca obtained full oncology rights to monalizumab in October 2018 through a co-development and commercialization agreement initiated in 2015.

article thumbnail

DARPA Neurotechnology: The Deep Dive

Codon

With a small cadre of engineers at USC and Wake Forest, Berger spent the next six years building and testing the device in rats and primates. This single achievement signaled, to some, a possible end to American engineering supremacy. And then, “we ran out of money,” he says. Eisenhower held a press conference.

article thumbnail

Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

The Pharma Data

2018) PLoS One. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Horsepox and vaccinia are closely related orthopoxviruses that are believed to share a common ancestor.

Vaccine 40